Please login to the form below
Abivax
This page shows the latest Abivax news and features for those working in and with pharma, biotech and healthcare.
Abivax enrols first patient in global phase 3 programme with obefazimod in ulcerative colitis
Abivax has enrolled the first patients in its global phase 3 clinical programme, ABTECT, with obefazimod for the treatment of moderate to severe ulcerative colitis (UC), the company announced. ... reported. Abivax outlined that 1, 200 UC patients will
Latest news
-
Abivax’s COVID-19 study declared Research National Priority by French government
Abivax is devoting significant efforts to this major international clinical trial and simultaneously accelerating ABX464 manufacturing scale-up for potential 2021 commercialisation,” he added. ... In July, Abivax treated the first patient in the phase
-
AbbVie, Amgen and Takeda team up for joint COVID-19 trial
French biotech company Abivax is also currently investigating its experimental ulcerative colitis drug ABX464 as an early treatment for elderly or high-risk patients with COVID-19.
-
Roche’s Actemra fails in late-stage severe COVID-19 study
Another anti-inflammatory drug, ABX464, is currently being studied by Abivax as an early treatment for elderly or high-risk patients with confirmed COVID-19.
-
Mesoblast expands compassionate use COVID-19 programme
A host of candidates are being investigated to regulate the overactive inflammatory side effects associated with some cases of COVID-19, including Abivax’s experimental anti-inflammatory med ABX464. ... Last week, Abivax initiated a phase 2b/3 study
-
Abivax doses first patient in phase 2b/3 COVID-19 clinical trial
Study will evaluate experimental anti-inflammatory drug. French biotech company Abivax has treated the first patient in a phase 2b/3 study of its experimental anti-inflammatory drug ABX464 in ... Currently, Abivax has received approval for studies in
More from news
Approximately 4 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
The race for a HIV ‘cure’
Another company working on a similar candidate is French biotech Abivax.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
Accession
Accession was a born from a passion and a vision. A passion to harness the power of market access to...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
